Oral News and Research

RSS

Viewpoints: GOP attack on Medicare, Medicaid could hurt critical programs; Will says Obama is repeating his overreach on health care

Congressional Republicans are insisting that big cuts to Medicare and Medicaid be on the table in the negotiations over the so-called fiscal cliff and deficit reduction. That stance is largely a political move against two programs, which have been critical to the public welfare for the past half-century.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced the presentation of data evaluating the preclinical safety and efficacy of two of the Company's novel, potent and selective small molecule inhibitors. These inhibitors individually target DOT1L and EZH2, members of a class of epigenic enzymes called histone methyltransferases (HMTs).

30 Nov 2012

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Regorafenib phase III results strongly support use in GIST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

29 Nov 2012

Nasolabial lip reconstruction provides favorable functional, aesthetic outcomes

Lip reconstruction with the musculocutaneous nasolabial flap following lip resection achieves good functional and aesthetic outcomes, research suggests.

29 Nov 2012

Patient adherence predicts ankle surgery healing

Focusing on postoperative care may be the optimal way of reducing healing complications following ankle fracture surgery, say US researchers.

29 Nov 2012

Periodontal disease identified using salivary biomarkers

Markers of inflammation found in saliva could be used to identify periodontal disease in large epidemiologic surveys, avoiding the need for cumbersome and expensive tests, suggest researchers.

29 Nov 2012

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).

28 Nov 2012

Children's caries history predicts future tooth decay

Having a history of dental caries significantly increases a child's chances of developing further caries, indicate study results.

27 Nov 2012

Simple measures halve ventilator-associated pneumonia

Adding a bundle of low-cost interventions to surveillance significantly reduces rates of ventilator-associated pneumonia in adult intensive care units in developing countries, shows an international study.

27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

With administration's support, Supreme Court orders review of 'Obamacare' challenge

The Supreme Court Monday told a lower court to consider several issues left unresolved by the justices' June ruling upholding the Affordable Care Act, in a move backed by the Obama administration.

27 Nov 2012

Some nicotine-free snus products can increase risk of caries

It is a myth that snus (Swedish snuff) users today have fewer dental caries. On the contrary, some types of nicotine-free snus contain both carbohydrates and starch that increase the risk of cavities. Those are the findings of a thesis from Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Nov 2012

Children with asthma benefit from cognitive behaviour therapy programme

Researchers have found that a programme of cognitive behaviour therapy delivered by nurses to children who had asthma and anxiety improved the children's quality of life scores and reduced the risk of escalation of treatment.

27 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Synta Pharmaceuticals Corp. announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan.

26 Nov 2012

Smoking-related diabetes a modifiable risk factor

Cigarette smoking is a modifiable risk factor for impaired insulin secretion in Japanese men, show study findings.

23 Nov 2012

Oral News and Research

Viewpoints: GOP attack on Medicare, Medicaid could hurt critical programs; Will says Obama is repeating his overreach on health care

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Epizyme to present data from DOT1L and EZH2 inhibitor programs at 54th ASH annual meeting

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Regorafenib phase III results strongly support use in GIST

Nasolabial lip reconstruction provides favorable functional, aesthetic outcomes

Patient adherence predicts ankle surgery healing

Periodontal disease identified using salivary biomarkers

Pfizer completes acquisition of NextWave Pharmaceuticals

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Children's caries history predicts future tooth decay

Simple measures halve ventilator-associated pneumonia

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

With administration's support, Supreme Court orders review of 'Obamacare' challenge

Some nicotine-free snus products can increase risk of caries

Children with asthma benefit from cognitive behaviour therapy programme

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Smoking-related diabetes a modifiable risk factor

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News